As the world faces an obesity "epidemic." the mechanisms by which overweigh
t is translated into insulin resistance, hypertension. and diabetes need to
be better understood. Although the processes of transition remain uncertai
n, overactivity of the sympathetic nervous system appears pivotal. In obesi
ty, there is stimulation of sympathetic outflow to the kidneys, evident in
increased rates of spillover of noradrenaline into the renal veins, and to
skeletal muscle vasculature, demonstrated with microneurography. The cause
is unclear, but possibly involves the stimulatory action of leptin released
from adipose tissue, or from within the brain. for which there is recent e
vidence in human obesity. The high renal sympathetic tone contributes to hy
pertension development by stimulating renin secretion and through promoting
renal tubular reabsorption of sodium. Neurally mediated skeletal muscle va
soconstriction reduces glucose delivery and uptake in muscle. Impairment of
glucose uptake by skeletal muscle is a hallmark of insulin resistance synd
romes. Pharmacologic sympathetic nervous suppression within the central ner
vous system with imidazoline receptor-binding agents such as rilmenidine is
a logical therapeutic approach for lowering blood pressure (BP) in patient
s with essential hypertension, in whom sympathetic activity is often increa
sed. In addition, drugs of this class appear to have the capacity to favora
bly modify insulin sensitivity, which has particular relevance in the treat
ment of hypertensive diabetic patients. In the hypertension accompanying ma
turity onset obesity, with recent recommendations from advisory bodies sett
ing lower goal BP, and with these lower targets often being reached only wi
th combinations of antihypertensive agents, it is advisable that all drugs
used in combination therapy have a favorable or at least a neutral effect o
n insulin resistance. (C) 2001 American Journal of Hypertension, Ltd.